{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:08:56Z","timestamp":1790244536361,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,1,20]],"date-time":"2019-01-20T00:00:00Z","timestamp":1547942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Research Agency","award":["ANR-11-PHUC-001"],"award-info":[{"award-number":["ANR-11-PHUC-001"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients suffering from B\u2010cell non\u2010Hodgkin lymphomas (B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>) have an increased likelihood of being exposed to proton pump inhibitors (<jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content>s), related to several factors which have been reported in the literature. <jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content>s are among the drugs most likely to be prescribed inappropriately. Consequently, B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> patients could be particularly at risk of inappropriate <jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content> prescription, with potential adverse drug reactions. We aimed to evaluate the incidence of <jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content>s use and to identify factors associated with <jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content>s initiation during the active treatment phase of B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>. We conducted a new\u2010user cohort study using regional data from the French national health insurance database in the Midi\u2010Pyr\u00e9n\u00e9es region (southwestern France). Incident B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> patients were selected according to an algorithm of selection, validated with data from a cancer registry. Our study revealed that 48.9% (95% confidence interval [<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>]: 45.2\u201352.6) of patients initiated <jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content>s during chemotherapy after B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> diagnosis. According to information available in the <jats:styled-content style=\"fixed-case\">SNDS<\/jats:styled-content>, recommended indications for <jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content> prescriptions were identified in 21.1% of cases. Median duration of treatment was 65.3\u00a0days (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 35\u2013112). Determinants of <jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content>s initiation were peptic ulcer disease, gastroprotection (appropriate or not) for medications considered at risk (<jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s, glucocorticoids and anticoagulants), age, nonfollicular lymphoma, polypharmacy, gastroenterologists\u2019 consultations and being hospitalized in a university hospital. Around 50% of patients initiated <jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content> treatment during the chemotherapy phase with only one\u2010fifth identified as appropriate prescriptions and with long durations of treatment in most cases. Given this background, appropriate <jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content> prescription should be promoted in B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> to avoid potential inappropriate chronic use and related adverse events.<\/jats:p>","DOI":"10.1111\/fcp.12436","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T17:12:32Z","timestamp":1547053952000},"page":"327-338","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Is there overuse of proton pump inhibitors in B\u2010cell non\u2010Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi\u2010Pyr\u00e9n\u00e9es region"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-5740","authenticated-orcid":false,"given":"C\u00e9cile","family":"Conte","sequence":"first","affiliation":[{"name":"UMR1027 INSERM Universit\u00e9 Paul Sabatier 37 all\u00e9es Jules Guesde 31000 Toulouse France"},{"name":"Laboratoire de Pharmacologie M\u00e9dicale et Clinique CHU de Toulouse 37 all\u00e9es Jules Guesde 31000 Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bourrel","sequence":"additional","affiliation":[{"name":"Caisse Nationale d'Assurance Maladie Midi\u2010Pyr\u00e9n\u00e9es 3 Boulevard L\u00e9opold Escande 31105 Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[{"name":"UMR1027 INSERM Universit\u00e9 Paul Sabatier 37 all\u00e9es Jules Guesde 31000 Toulouse France"},{"name":"Laboratoire de Pharmacologie M\u00e9dicale et Clinique CHU de Toulouse 37 all\u00e9es Jules Guesde 31000 Toulouse France"},{"name":"INSERM CIC 1436 Toulouse Centre d'Investigation Clinique de Toulouse Centre Hospitalier Universitaire de Toulouse Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"additional","affiliation":[{"name":"UMR1027 INSERM Universit\u00e9 Paul Sabatier 37 all\u00e9es Jules Guesde 31000 Toulouse France"},{"name":"Laboratoire de Pharmacologie M\u00e9dicale et Clinique CHU de Toulouse 37 all\u00e9es Jules Guesde 31000 Toulouse France"},{"name":"INSERM CIC 1436 Toulouse Centre d'Investigation Clinique de Toulouse Centre Hospitalier Universitaire de Toulouse Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2171-x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2011.09.001"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400403s"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216307082661"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.115"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1281110"},{"key":"e_1_2_8_8_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2010 Les inhibiteurs de la pompe \u00e0 protons chez l'adulte \u2010 Fiche BUM[Internet]. [cit\u00e9 18 mai 2017]. Disponible sur:https:\/\/www.has-sante.fr\/\/portail\/jcms\/r_1439925\/fr\/les-inhibiteurs-de-la-pompe-a-protons-chez-l-adulte-fiche-bum"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00839.x"},{"key":"e_1_2_8_10_1","first-page":"122","article-title":"Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization","volume":"16","author":"Thomas L.","year":"2010","journal-title":"J. Manag. Care Pharm."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14528"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39406.449456.BE"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182151be7"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.01.025"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0718-z"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.10.007"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02921.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.23.2989"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1560-3"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.05.018"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.031"},{"key":"e_1_2_8_22_1","unstructured":"O'NeillL.W. CulpepperB.L. GaldoJ.A.Long\u2010term consequences of chronic proton pump inhibitor use[Internet].2013[cit\u00e9 22 mars 2017]. Disponible sur:https:\/\/www.uspharmacist.com\/article\/longterm-consequences-of-chronic-proton-pump-inhibitor-use"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016644469"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015735"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-015-0178-0"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.01.014"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0144-0"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0431"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12214"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","unstructured":"ConteCA.Novel approach for medical research on lymphomas: A study validation of claims\u2010based algorithms to identify incident cases. Medicine (Baltimore) (2018)97e9418.https:\/\/doi.org\/10.1097\/MD.0000000000009418","DOI":"10.1097\/MD.0000000000009418"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3331-y"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2017.06.003"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2350"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2010.497935"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03445.x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141779"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb00855.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.797961"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.05.017"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13649"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.12436","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T17:30:12Z","timestamp":1694367012000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,20]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/fcp.12436"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12436","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,20]]},"assertion":[{"value":"2018-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}